Chromadex Corp (NASDAQ: CDXC) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock.
ChromaDex Corporation (CDXC)
NASDAQ:AMEX Investor Relations:
investors.chromadex.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
CDXC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXC alerts
High impacting ChromaDex Corporation news events
Weekly update
A roundup of the hottest topics
CDXC
News
- Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why [Yahoo! Finance]Yahoo! Finance
- ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement [Yahoo! Finance]Yahoo! Finance
- ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity SupplementBusiness Wire
- ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
CDXC
Earnings
- 10/31/24 - Beat
CDXC
Sec Filings
- 11/21/24 - Form 8-K
- 11/8/24 - Form 3
- 10/31/24 - Form 8-K
- CDXC's page on the SEC website